This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Opinion: Discussing the recent FDA approval of LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy.
Ticker(s): AVDLWho's the expert?
Institution: SAS Specialists
- Manages 400 patients with narcolepsy and sees about 100 patients a month for insomnia
- dual board certified in internal medicine and sleep medicine.
- Sleep physician and CMO at the center for sleep medicine, managing OSA, CSA, Narcolepsy, RLS, RBD, etc. for adult and pediatric patients
Interview GoalTo discuss the recent FDA approval and published literature on Avadel's LUMRYZ (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
